- Home
- ADMA vs ACLX Comparison
ADMA vs ACLX Comparison
Compare ADMA & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADMA
- ACLX
- Stock Information
- Founded
- ADMA 2004
- ACLX 2015
- Country
- ADMA United States
- ACLX United States
- Employees
- ADMA N/A
- ACLX N/A
- Industry
- ADMA Biotechnology: Biological Products (No Diagnostic Substances)
- ACLX Biotechnology: Pharmaceutical Preparations
- Sector
- ADMA Health Care
- ACLX Health Care
- Exchange
- ADMA Nasdaq
- ACLX Nasdaq
- Market Cap
- ADMA 3.7B
- ACLX 4.4B
- IPO Year
- ADMA N/A
- ACLX 2022
- Fundamental
- Price
- ADMA $15.05
- ACLX $84.84
- Analyst Decision
- ADMA Strong Buy
- ACLX Strong Buy
- Analyst Count
- ADMA 3
- ACLX 12
- Target Price
- ADMA $27.67
- ACLX $113.08
- AVG Volume (30 Days)
- ADMA 3.1M
- ACLX 559.6K
- Earning Date
- ADMA 11-06-2025
- ACLX 11-06-2025
- Dividend Yield
- ADMA N/A
- ACLX N/A
- EPS Growth
- ADMA 469.09
- ACLX N/A
- EPS
- ADMA 0.85
- ACLX N/A
- Revenue
- ADMA $474,174,000.00
- ACLX $56,979,000.00
- Revenue This Year
- ADMA $21.17
- ACLX N/A
- Revenue Next Year
- ADMA $26.03
- ACLX $210.73
- P/E Ratio
- ADMA $17.41
- ACLX N/A
- Revenue Growth
- ADMA 43.58
- ACLX N/A
- 52 Week Low
- ADMA $13.50
- ACLX $47.86
- 52 Week High
- ADMA $25.67
- ACLX $107.37
- Technical
- Relative Strength Index (RSI)
- ADMA 47.74
- ACLX 52.93
- Support Level
- ADMA $14.35
- ACLX $84.60
- Resistance Level
- ADMA $15.60
- ACLX $94.07
- Average True Range (ATR)
- ADMA 0.52
- ACLX 3.85
- MACD
- ADMA 0.13
- ACLX -0.59
- Stochastic Oscillator
- ADMA 65.17
- ACLX 18.76
About ADMA ADMA Biologics Inc
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.